Mark Zuckerberg and Priscilla Chan’s $45 billion philanthropy organization is making its first acquisition in order to make it easier for scientists to search, read and tie together more than 26 million science research papers. The Chan Zuckerberg Initiative is acquiring Meta, an AI-powered r…
Toronto-based startup Sciencescape came about because of a problem that was significant enough to lure co-founder Sam Molyneux away from a bourgeoning career as a cancer researcher, and into a new venture that wants to tackle the bigger picture issue of fixing the entire system of academic, medical…
Open science can lead to greater collaboration, increased confidence in findings and goodwill between researchers.
I once asked Robert McEliece whether he would mentor me. I told him I liked combinatorics and it seemed relevant for EE. He explained that "you find an interesting problem and then use the relevant tools, not the other way around." Formative experience. https://t.co/3IDTgdSJsF
— Lior Pachter (@lpachter) May 13, 2019
Despite steadily declining rates of cancer deaths over the past two decades, cancer remains responsible for 1 in every 6 deaths worldwide. It’s a scourge. So when, this week, an Israeli company called Accelerated Evolution Biotechnologies captured the news cycle with promises of a complete cure for cancer within the year, the story caught fire.
The company’s technology is called “MuTaTo” — that's multi-target toxin. And, to judge from the news media this week, it seems vetted, verified and veering us all toward a cancer-free future. Reports began in the Jerusalem Post, but quickly took off, making their way into various Murdoch-owned publications like FOX and the New York Post and landing in local news outlets around the country and the globe.
A couple days into the fanfare, the skeptics started coming out: for one thing, as oncologist David Gorski points out in his blog “Respectful Insolence,” the claims are based on experiments with mice: no human trials have yet started. For another, they haven’t been sufficiently peer reviewed. In fact, the company won’t share its research, claiming it can’t afford the expense. The too-good-to-be-true story appears to be just that, built on PR puffery. But who can resist a good cancer cure?
With Mutato in mind, for this week’s podcast extra, we revisit our Breaking News Consumer’s Handbook: Health News edition, with Gary Schwitzer, publisher & founder of HealthNewsReview.org.
Although it’s been a while since I last taught Research Methods or Research Design, I am collaborating with my department’s working group on research methods. We are redesigning courses, syllabi and sequences, so I am always keen on reading and keeping up-to-date with methodological advances. Mo...
In 1994, Ron Clarke, a paleoanthropologist at the University of the Witwatersrand in Johannesburg, South Africa, was looking through some museum boxes filled with fossil specimens from the Sterkfontein caves, located about 40 kilometers northwest of the city. Beginning in the 1930s, a number of hominin fossils had been found there, mostly australopithecines, in what South Africans call the Cradle of Humankind. Clarke quickly realized that four of the fossils, all small toe bones, had been misidentified as belonging to monkeys. They actually belonged to an early hominin, most likely another australopithecine. It quickly became known as "Little Foot."